Natixis’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-291
| Closed | -$70.7K | – | 939 |
|
|
2024
Q2 | $70.7K | Sell |
291
-391
| -57% | -$95K | ﹤0.01% | 751 |
|
|
2024
Q1 | $102K | Buy |
+682
| New | +$102K | ﹤0.01% | 754 |
|
|
2022
Q4 | – | Sell |
-226,034
| Closed | -$45.3M | – | 1013 |
|
|
2022
Q3 | $45.3M | Buy |
226,034
+218,295
| +2,821% | +$43.7M | 0.21% | 80 |
|
|
2022
Q2 | $1.13M | Buy |
7,739
+5,373
| +227% | +$784K | ﹤0.01% | 755 |
|
|
2022
Q1 | $386K | Sell |
2,366
-101,696
| -98% | -$16.6M | ﹤0.01% | 1022 |
|
|
2021
Q4 | $17.6M | Buy |
104,062
+1,546
| +2% | +$262K | 0.06% | 271 |
|
|
2021
Q3 | $19.4M | Buy |
102,516
+94,044
| +1,110% | +$17.8M | 0.07% | 242 |
|
|
2021
Q2 | $1.44M | Buy |
8,472
+1,961
| +30% | +$332K | 0.01% | 570 |
|
|
2021
Q1 | $919K | Buy |
6,511
+4,525
| +228% | +$639K | ﹤0.01% | 845 |
|
|
2020
Q4 | $258K | Sell |
1,986
-616
| -24% | -$80K | ﹤0.01% | 973 |
|
|
2020
Q3 | $379K | Buy |
+2,602
| New | +$379K | ﹤0.01% | 633 |
|